SYK - Stryker Corporation
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results.
On June 30, 2026, Stryker Corp (SYK) shares fell 4.7% to a current price of $314.84. This decline comes in a challenging year where the stock has seen a year-to
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PORTAGE, Mich., June 24, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Vistra Corp. (NYSE:VST), adding it “went too high. It's come back down.
Stryker faces cyberattack fallout, but strong procedure demand, record Mako adoption and global expansion continue to support long-term growth.
SYK launches TPX HD, a small bone power tool built for complex revisions, MIS and oral maxillofacial cases with higher torque and speed.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
On June 02, 2026, we present a DCF analysis for Stryker Corp (SYK) amidst its recent price performance, which has seen a decline of 14.6% year-to-date and 21.0%
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
Stryker (NYSE: SYK), a global leader in medical technologies, announced today the European launch of its [url="]Pangea Plating System[/url], a plating platform
AMSTERDAM--(BUSINESS WIRE)--Stryker announced the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns.
CHARLEVOIX, Mich.--(BUSINESS WIRE)--BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in.
BOSTON--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication. The POWER CAD I study will evaluate the feasibility of the Pulse IVL™ System for the treatment of patients with moderate to severely calcified coronary arteri.